Welcome To The BlockRx™ Token Sale

BlockRx

Blog

Finally, 2017!  For those of us involved in Blockchain Pharma initiatives, 2017 is going to be a very exciting and challenging year!  The Pharma industry, which include Providers, Manufacturers, Wholesalers, 3PL and Retailers are working diligently to expand their Blockchain footprint by leveraging additional business units to utilize the Blockchain  as a method to provide…

Read More

The Drug Development Chain (Discoveryà R&D-à Pre-Clinical testingà Clinical Testingà Regulatory ApprovalàMarket Release) is the long, arduous, and expensive process that a therapy takes from idea to cure. The process requires experts from a broad spectrum of disciplines and the ability to collect, analyze, and collate data housed in multiple internal and external systems that…

Read More

All people require some type of motivation to perform well at work or school. Some are motivated by public recognition, frequent flyer miles, the feeling of overcoming a challenge, or even a nice evening out. What is less obvious is that people require incentives to maintain a healthy lifestyle or improve adherence. It would seem…

Read More

As the biopharma industry moves toward personalized medicine, there will be a greater need to exchange patient data with organizations that are not part of the “traditional” healthcare team. The concern being that such data, if centralized like credit card information, could become a target for a cyberattack. Imagine, for example, a high profile business…

Read More

Investors face multiple challenges in identifying the right portfolio company for their funds. Currently, only about 1/3rd of investments return the 3.5-5x Cash on Cash returns expected of a successful VC firm. On the other side of the coin, companies have a difficult time connecting with the right investors and Investment Associates spend a lot…

Read More

According to the Pharmaceutical Research and Manufacturers of America (PhRMA), it costs on average of $2.6 billion and takes 10-15 years to bring a new medication to market. This is a lengthy and complex process. Throughout the Therapeutic Development Lifecycle, there is a need for a wide range of expertise, financing, and IP to accomplish…

Read More

According to the United States Patent Office, the top 250 Universities spent $62 million on R&D and filed over 4,000 patents in 2011. These patents and the subsequent licenses generate revenue that can be reinvested in further research, improving infrastructure, and the student experience. In 2014, the World Intellectual Property Organization stated that 2.7M patents…

Read More

When people think of the term healthcare, they see it as a solid color puzzle. In reality, the term should be seen as a mosaic made up of Providers, Payers, Regulators, Suppliers, and Manufacturers. However one thinks of healthcare, it is important to keep in mind that there is no true interconnectivity between all of…

Read More

A case can be made that DNA (Deoxyribonucleic Acid) is the first example of ADLT™. It is decentralized, ubiquitous, requires verification, and has worked for millions of years. Its modern equivalent also shares many of the same characteristic features. Most people do not understand that what is unique about e-DNA (i.e ADLT™) is that it…

Read More

Whether you are a pharmacist, wholesaler, or manufacturer, you realize that the medication recall process requires drastic improvement. I have experienced this first hand as a pharmacist. There were several times when patients would come to the pharmacy and tell me they heard their medication was recalled; I hadn’t even received a fax notification about…

Read More